Researchers from Exscientia plc presented preclinical data for the novel reversible LSD1 inhibitor EXS-74539, being developed as a monotherapy or in combination with standard of care for the treatment of oncology and hematology indications including acute myeloid leukemia (AML) and small-cell lung cancer.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is a key regulator of immune signaling that supports proliferation and promotes metastasis while maintaining the tumor microenvironment under immunosuppression. Researchers from Exscientia plc and Evotec SE reported on the characterization of EXS-73565.
Glutaminyl-peptide cyclotransferase-like protein (QPCTL) is a modulator of CD47-SIRPα binding and can be targeted to achieve antitumor responses through myeloid checkpoint blockade. At the recent ESMO meeting in Madrid, researchers from Insilico Medicine Inc. reported the preclinical characterization of ISM-8207, a QPCTL inhibitor with activity against triple-negative breast cancer (TNBC) and diffuse large B-cell lymphoma (DLBCL).
Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?
Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.
RSS
